<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01584739</url>
  </required_header>
  <id_info>
    <org_study_id>D1883C00002</org_study_id>
    <secondary_id>Eudract 2011-005588-25</secondary_id>
    <nct_id>NCT01584739</nct_id>
  </id_info>
  <brief_title>AZD8683 Multiple Dose Study in Healthy Volunteers and Chronic Obstructive Pulmonary Disease (COPD) Patients</brief_title>
  <official_title>A Phase I, Single Centre, Double-Blind, Randomised, Placebo- Controlled, Parallel-group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Inhaled Doses of AZD8683 in Healthy Volunteers and COPD Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      This study will investigate the safety, tolerability, pharmacokinetics and pharmacodynamics
      of multiple ascending inhaled doses of AZD8683 in Healthy volunteers and repeated inhalation
      of one dose level of AZD8683 in patients with chronic obstructive pulmonary disease given
      once daily.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase I, Single Centre, Double-Blind, Randomised, Placebo- controlled, Parallel-group Study
      to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple
      Ascending Inhaled Doses of AZD8683 in Healthy Volunteers and COPD patients
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety profile in terms of: adverse events, Supine vital signs (blood pressure and pulse rate), body temperature, ECG, Physical examinations, Laboratory variables (clinical chemistry, haematology and urinalysis), Spirometry</measure>
    <time_frame>Up to 13 days post dose.</time_frame>
    <description>No formal statistical tests will be performed</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AZD8683 single dose pharmacokinetics from blood and urine in healthy volunteers.</measure>
    <time_frame>Blood: From days 1 and 15 - Pre-dose, 5, 15 and 30mons, 1, 1.5, 2, 4, 6, 8, 12, 24, 36, 48, 72 hrs (also 96 and 120hrs and follow-up). Urine: From days 1 and 15: pre-dose and 6, 12, 24, 48 and 72hrs.</time_frame>
    <description>PK parameters:Cmax; tmax -Time to max plasma concentration; t½ λz,AUC-Area under the plasma concentration time curve from zero to infinity;AUC(0-t)-Area under plasma concentration time curve from zero to time of the last measurable concentration; AUC(0-24);AUC(0-72)-Area under the plasma concentration-time curve from zero to 72 hours; CL/F; Vz/F-Apparent volume of distribution during terminal phase; MRT-Mean residence time; Ae; Ae(0-t)-Cumulative amount of AZD8683 excreted unchanged in urine from zero (predose) to time t; fe-Fraction of dose excreted unchanged in urine; CLR-Renal clearance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AZD8683 multiple dose pharmacokinetics from blood and urine in healthy volunteers.</measure>
    <time_frame>Blood: From days 1 and 15 - Pre-dose, 5, 15 and 30mins, 1, 1.5, 2, 4, 6, 8, 12, 24, 36, 48, 72 hrs (also 96 and 120hrs and follow-up). Urine: From days 1 and 15: pre-dose and 6, 12, 24, 48 and 72hrs.</time_frame>
    <description>PK paramaters:Cmax and Cmin (max and min plasma concentration);tmax;t½ λz-Terminal half-life; AUC(0-τ)-Area under the plasma concentration-time curve during the dosing interval; Cav-Average plasma concentration;CL/F-Apparent plasma clearance; Rac AUC(0-τ)-Accumulation ratio of AUC(0-τ)compared to AUC(0-24)Day1;Rac Cmax-Accumulation ratio of Cmax compared to Cmax Day 1;Ae(t1-t2), Ae(0-τ)-Amount of drug excreted unchanged in urine in a collection interval; and to the end of the dosing interval respectively;fe(0-τ)-fraction of drug excreted unchanged in urine during a dosing interva;CLR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of the pharmacodynamic (PD) effects of AZD8683 in healthy volunteers in terms of : FEV1 and FVC.</measure>
    <time_frame>Predose, 5mins, 30mins, 1hr, 2hrs, and 4hrs on days 1 and 15.</time_frame>
    <description>Average effect over the first 4 hrs (Eav, AUEC(0-4)/4 hours).Peak effect during the first 4 hrs (Emax).FEV = Forced Expiratory Volume in 1 second. FVC = Forced Vital Capacity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of the pharmacodynamic (PD) effects of AZD8683 in COPD patients in terms of : FEV1 and FVC.</measure>
    <time_frame>Predose, 5mins, 30mins, 1hr, 2hrs and 4hrs on days 1 and 12.</time_frame>
    <description>Average effect over the first 4 hrs (Eav, AUEC(0-4)/4 hours).Peak effect during the first 4 hrs (Emax).FEV = Forced Expiratory Volume in 1 second. FVC = Forced Vital Capacity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of the pharmacodynamic (PD) effects of AZD8683 in healthy volunteers in terms of : supine blood pressures and pulse rate.</measure>
    <time_frame>Pre-dose, 30mins, 60mins, 90 mins, 2hrs and 4hrs, on days 1 and 15.</time_frame>
    <description>Average effect over the first 4 hrs (Eav, AUEC(0-4)/4 hours).Peak effect during the first 4 hrs (Emax). For diastolic blood pressure the minimum value(Emin), will be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of the pharmacodynamic (PD) effects of AZD8683 in COPD patients in terms of : supine blood pressures and pulse rate.</measure>
    <time_frame>Pre-dose, 30mins, 60mins, 90 mins, 2hrs and 4hrs on days 1 and 12.</time_frame>
    <description>Average effect over the first 4 hrs (Eav, AUEC(0-4)/4 hours).Peak effect during the first 4 hrs (Emax). For diastolic blood pressure the minimum value(Emin), will be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of the pharmacodynamic (PD) effects of AZD8683 in healthy volunteers in terms of : QT interval corrected for heart rate using Fridericia's formula and heart rate.</measure>
    <time_frame>30mins pre-dose and 25 mins, 5mins, 1hr 25 mins, 1hr 55 mins and 3 hr 55 mins, on days 1 and 15.</time_frame>
    <description>Average effect over the first 4 hrs (Eav, AUEC(0-4)/4 hours).Peak effect during the first 4 hrs (Emax).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of the pharmacodynamic (PD) effects of AZD8683 in COPD patients in terms of : QT interval corrected for heart rate using Fridericia's formula and heart rate.</measure>
    <time_frame>30mins pre-dose and 25 mins, 5mins, 1hr 25 mins, 1hr 55 mins and 3 hr 55 mins on days 1 and 12.</time_frame>
    <description>Average effect over the first 4 hrs (Eav, AUEC(0-4)/4 hours).Peak effect during the first 4 hrs (Emax).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>COPD</condition>
  <arm_group>
    <arm_group_label>AZD8683</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo to AZD8683</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD8683</intervention_name>
    <description>Multiple dose, oral inhalation (Healthy volunteers) Multiple dose, oral inhalation (COPD patients)</description>
    <arm_group_label>AZD8683</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Multiple dose, oral inhalation (Healthy volunteers) Multiple dose, oral inhalation (COPD patients</description>
    <arm_group_label>Placebo to AZD8683</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male volunteers and healthy female volunteers of non-child bearing potential,
             aged 18 to 45 years inclusive with suitable veins for cannulation or repeated
             venepuncture - Healthy volunteers

          -  Have a body mass index (BMI) between 19 and 30 kg/m2 and weigh at least 50 kg and no
             more than 100 kg inclusive - Healthy volunteers and COPD patients

          -  Be able to inhale from the Turbuhaler® inhaler according to given instructions as well
             as be able to perform spirometry -Healthy volunteers and COPD patients.

          -  Male COPD patients or female COPD patients of non-childbearing potential (post
             menopausal or surgically sterilised) aged ≥40 years at Visit 1 - COPD patients

          -  Female healthy volunteers and female patients ≤60 years must have a negative pregnancy
             test at screening and on admission to the unit - Healthy volunteers and COPD patients

        Exclusion Criteria:

          -  Prolonged QTcF &gt;450 ms or shortened QTcF &lt;340 ms or family history of long QT syndrome
             - Healthy volunteers and COPD patients

          -  History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity, as
             judged by the investigator or history of hypersensitivity to drugs with a similar
             chemical structure or class to AZD8683 or excipients:Healthy volunteers and COPD
             patients

          -  History or presence of gastrointestinal, pulmonary, hepatic or renal disease or any
             other condition known to interfere with absorption, distribution, metabolism or
             excretion of drugs - Healthy volunteers and COPD patients

          -  Any clinically significant illness (other than COPD), medical/surgical procedure or
             trauma within 4 weeks of the first administration of investigational product - COPD
             patients

          -  Any clinically significant illness, medical/surgical procedure or trauma within 4
             weeks of the first administration of investigational product - Healthy volunteers
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carin Jorup</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca Research and Development SE-431 83 Molndal Sweden</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 2, 2012</study_first_submitted>
  <study_first_submitted_qc>April 24, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2012</study_first_posted>
  <last_update_submitted>November 30, 2012</last_update_submitted>
  <last_update_submitted_qc>November 30, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 3, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Safety</keyword>
  <keyword>tolerability</keyword>
  <keyword>healthy</keyword>
  <keyword>COPD (chronic obstructive pulmonary disease)</keyword>
  <keyword>pharmacokinetic</keyword>
  <keyword>pharmacodynamic</keyword>
  <keyword>inhaled</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

